Total Payments
$929,207
2024 Payments
$54,522
Companies
35
Transactions
1,863
Medicare Patients
2,379
Medicare Billing
$343,272
Payment Breakdown by Category
Other$805,126 (86.6%)
Food & Beverage$42,537 (4.6%)
Consulting$41,694 (4.5%)
Travel$37,972 (4.1%)
Research$1,299 (0.1%)
Education$523.65 (0.1%)
Gifts$55.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $805,126 | 392 | 86.6% |
| Food and Beverage | $42,537 | 1,112 | 4.6% |
| Consulting Fee | $41,694 | 21 | 4.5% |
| Travel and Lodging | $37,972 | 317 | 4.1% |
| Unspecified | $1,299 | 6 | 0.1% |
| Education | $523.65 | 14 | 0.1% |
| Gift | $55.00 | 1 | 0.0% |
Payments by Type
General
$927,908
1,857 transactions
Research
$1,299
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $285,672 | 398 | $0 (2024) |
| ABBVIE INC. | $232,600 | 503 | $0 (2024) |
| Celgene Corporation | $202,298 | 254 | $0 (2019) |
| PFIZER INC. | $100,874 | 238 | $0 (2023) |
| Lilly USA, LLC | $44,165 | 84 | $0 (2023) |
| Arcutis Biotherapeutics, Inc. | $20,764 | 26 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $16,474 | 56 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $9,762 | 21 | $0 (2022) |
| Encore Dermatology Inc. | $4,009 | 17 | $0 (2018) |
| UCB, Inc. | $2,760 | 25 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $54,522 | 69 | Amgen Inc. ($41,867) |
| 2023 | $101,984 | 134 | Amgen Inc. ($71,694) |
| 2022 | $134,739 | 292 | Amgen Inc. ($57,960) |
| 2021 | $133,527 | 260 | Amgen Inc. ($78,274) |
| 2020 | $77,775 | 206 | Amgen Inc. ($32,131) |
| 2019 | $205,909 | 343 | Celgene Corporation ($98,136) |
| 2018 | $120,279 | 291 | Celgene Corporation ($71,431) |
| 2017 | $100,473 | 268 | AbbVie, Inc. ($39,208) |
All Payment Transactions
1,863 individual payment records from CMS Open Payments — Page 1 of 75
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/05/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Inflammation | ||||||
| 09/05/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Inflammation | ||||||
| 09/05/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Inflammation | ||||||
| 09/05/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Inflammation | ||||||
| 09/05/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: Inflammation | ||||||
| 09/05/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $28.14 | General |
| Category: Inflammation | ||||||
| 09/05/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $16.75 | General |
| Category: Inflammation | ||||||
| 09/05/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $13.40 | General |
| Category: Inflammation | ||||||
| 09/05/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $3.00 | General |
| Category: Inflammation | ||||||
| 09/05/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $3.00 | General |
| Category: Inflammation | ||||||
| 09/05/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $3.00 | General |
| Category: Inflammation | ||||||
| 09/05/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $2.01 | General |
| Category: Inflammation | ||||||
| 09/02/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Inflammation | ||||||
| 09/02/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| Category: Inflammation | ||||||
| 08/30/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $24.35 | General |
| Category: Inflammation | ||||||
| 08/29/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $27.65 | General |
| Category: Inflammation | ||||||
| 08/28/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $68.34 | General |
| Category: Inflammation | ||||||
| 08/28/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $60.30 | General |
| Category: Inflammation | ||||||
| 08/28/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $20.00 | General |
| Category: Inflammation | ||||||
| 08/27/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $22.06 | General |
| Category: Inflammation | ||||||
| 08/26/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Inflammation | ||||||
| 08/26/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| Category: Inflammation | ||||||
| 08/26/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: Inflammation | ||||||
| 08/21/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $23.36 | General |
| Category: IMMUNOLOGY | ||||||
| 08/20/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $140.75 | General |
| Category: Inflammation | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TRALOKINUMAB VACCINE RESPONSE TIME | LEO Pharma AS | $1,299 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 483 | 719 | $143,472 | $58,757 |
| 2022 | 12 | 595 | 873 | $218,133 | $96,129 |
| 2021 | 12 | 625 | 928 | $216,840 | $107,203 |
| 2020 | 10 | 676 | 936 | $168,740 | $81,183 |
Total Patients
2,379
Total Services
3,456
Medicare Billing
$343,272
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 166 | 291 | $61,384 | $24,697 | 40.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 80 | 134 | $26,598 | $12,194 | 45.8% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2023 | 25 | 55 | $12,654 | $5,446 | 43.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 46 | 46 | $12,568 | $4,701 | 37.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 45 | 51 | $9,038 | $3,706 | 41.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 45 | 57 | $8,530 | $3,514 | 41.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 34 | 34 | $6,275 | $1,724 | 27.5% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 11 | 11 | $2,408 | $1,124 | 46.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 18 | 21 | $1,834 | $958.44 | 52.3% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 13 | 19 | $2,183 | $693.07 | 31.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 217 | 394 | $82,774 | $35,901 | 43.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 129 | 129 | $35,418 | $13,606 | 38.4% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2022 | 31 | 86 | $19,731 | $10,090 | 51.1% |
| 17312 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | Office | 2022 | 13 | 20 | $14,089 | $7,467 | 53.0% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2022 | 15 | 17 | $19,371 | $7,194 | 37.1% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2022 | 15 | 16 | $7,860 | $4,328 | 55.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 33 | 48 | $9,020 | $4,258 | 47.2% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 20 | 30 | $8,213 | $3,936 | 47.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 40 | 44 | $8,046 | $3,503 | 43.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 36 | 36 | $6,667 | $2,695 | 40.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 29 | 32 | $4,784 | $1,908 | 39.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 17 | 21 | $2,162 | $1,243 | 57.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 205 | 398 | $77,850 | $38,514 | 49.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 151 | 151 | $38,520 | $17,031 | 44.2% |
| 17311 | Removal and microscopic examination of growth of the head, neck, hands, feet, or genitals (first stage, up to 5 tissue blocks) | Office | 2021 | 19 | 25 | $25,000 | $11,778 | 47.1% |
About Dr. Christopher Ho, MD
Dr. Christopher Ho, MD is a Dermatology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1679507537.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Ho, MD has received a total of $929,207 in payments from pharmaceutical and medical device companies, with $54,522 received in 2024. These payments were reported across 1,863 transactions from 35 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($805,126).
As a Medicare-enrolled provider, Ho has provided services to 2,379 Medicare beneficiaries, totaling 3,456 services with total Medicare billing of $343,272. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Los Angeles, CA
- Active Since 07/10/2006
- Last Updated 02/10/2025
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1679507537
Products in Payments
- Otezla (Drug) $477,461
- EUCRISA (Drug) $83,990
- Humira (Biological) $66,759
- SKYRIZI (Biological) $54,422
- RINVOQ (Biological) $52,455
- TALTZ (Drug) $43,449
- Skyrizi (Biological) $37,267
- COSENTYX (Biological) $16,474
- Zoryve (Drug) $10,554
- HUMIRA (Biological) $7,747
- CIBINQO (Drug) $7,664
- Otezla (Biological) $3,419
- VTAMA (Drug) $2,700
- DUPIXENT (Biological) $1,001
- Tremfya (Drug) $649.67
- Enbrel (Biological) $614.44
- DORYX (Drug) $529.82
- Acticlate (Drug) $486.80
- Cimzia (Drug) $399.70
- Hylatopic (Drug) $256.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Los Angeles
Dr. Howard Sofen, M.d, M.D
Dermatology — Payments: $654,301
Dermatology $654,301
Jennifer Hsiao, M.d, M.D
Dermatology — Payments: $400,325
Dermatology $400,325
Dr. Pearl Grimes, Md, MD
Dermatology — Payments: $358,500
Dermatology $358,500
Derek Jones, Md, MD
Dermatology — Payments: $316,086
Dermatology $316,086
Rebecca Fitzgerald, M.d, M.D
Dermatology — Payments: $281,818
Dermatology $281,818
Nada Elbuluk, Md, MD
Dermatology — Payments: $205,242
Dermatology $205,242